Screener
Kura Oncology KURA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 65,263 | 55,973 |
| Selling, general and administrative | 31,555 | 22,835 |
| Total operating expenses | 97,080 | 78,808 |
| Loss from operations | (78,815) | (64,700) |
| Other Income (Expense) | ||
| Interest and other income, net | 5,826 | 7,879 |
| Interest expense | (336) | (382) |
| Total other income, net | 5,490 | 7,497 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's operating income?
- Kura Oncology (KURA) reported operating income of -$78.82M in Q1 2026.
- How has Kura Oncology's operating income changed year-over-year?
- Kura Oncology's operating income decreased by 21.8% year-over-year, from -$64.7M to -$78.82M.
- What is the long-term trend for Kura Oncology's operating income?
- Over 3 years (2022 to 2025), Kura Oncology's operating income has grown at a 29.5% compound annual growth rate (CAGR), from -$139.87M to -$303.63M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Kura Oncology's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude